Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dimerix Limited ( (AU:DXB) ) has shared an announcement.
Dimerix Limited has announced the issuance of 41,710 fully paid ordinary shares following the cashless exercise of 250,000 unlisted options. This strategic move, compliant with relevant sections of the Corporations Act, reflects the company’s ongoing efforts to optimize its capital structure and enhance shareholder value.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited operates in the biotechnology industry, focusing on developing innovative therapies for unmet medical needs. The company is known for its work in drug discovery and development, particularly in the areas of kidney disease and other inflammatory conditions.
Average Trading Volume: 2,006,601
Technical Sentiment Signal: Buy
Current Market Cap: A$312.1M
See more insights into DXB stock on TipRanks’ Stock Analysis page.